Cerulean’s second candidate from its clinically validated platform, CRLX301, designed to act as a tubulin inhibitor, capitalizes on the strengths of its payload, docetaxel. Docetaxel, while a very successful therapy, has significant side effects. Non-clinical data has demonstrated that Cerulean’s NDCs platform has the potential to dramatically improve both the safety and effectiveness of docetaxel, while enabling therapeutic benefits in multi-drug resistant tumor models where docetaxel has previously exhibited little activity. CRLX301 is the marriage of a commercially validated payload and a clinically validated platform.

Clinical development program

In late 2014, Cerulean intends to commence a Phase 1 clinical trial to assess the safety of CRLX301. The goal of the trial will be to determine maximum tolerated dose and dose regimen for CRLX301.